Rumi Scientific

Rumi Scientific's mission is to leverage its revolutionary synthetic human tissue platform to generate more predictive data, enabling a safe and rapid clinical trial process to identify and develop new therapies for rare diseases and neurodegenerative conditions. The company’s lead program is an orally administered bromodomain-containing protein 9 (BRD9) inhibitor for the lead optimization treatment of Huntington's disease.